NextCell Pharma AB
F:65G
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
NextCell Pharma AB
F:65G
|
SE |
|
Ascencio SCA
F:ZYY
|
BE |
|
WuXi AppTec Co Ltd
SSE:603259
|
CN |
|
P
|
Plexus Holdings PLC
XBER:P3H
|
UK |
|
R
|
Roche Holding AG
DUS:RHO
|
CH |
|
P
|
Pebble Beach Systems Group PLC
LSE:PEB
|
UK |
|
eXp World Holdings Inc
F:44Y
|
US |
NextCell Pharma AB
NextCell Pharma AB is a Swedish life science company built around stem cells. It develops stem cell-based treatments for inflammatory and autoimmune diseases, and it also runs a stem cell banking business that stores cells collected from umbilical cord blood and tissue for families who want to keep them for future medical use. The company makes money in two main ways. One is through its stem cell bank, which charges families for collection, processing, and long-term storage services. The other is through its drug development work, where it advances cell therapy candidates such as ProTrans and may earn value through research partnerships, licensing, or future commercialization if its therapies reach the market. What makes NextCell different is that it sits in two parts of the stem cell value chain at once: it handles storage today while also trying to turn stem cells into medicines for tomorrow. That gives the company a mix of service revenue and higher-risk biotech development, and its customers range from private families using the bank to hospitals, researchers, and future patients who could benefit from its cell therapies.
NextCell Pharma AB is a Swedish life science company built around stem cells. It develops stem cell-based treatments for inflammatory and autoimmune diseases, and it also runs a stem cell banking business that stores cells collected from umbilical cord blood and tissue for families who want to keep them for future medical use.
The company makes money in two main ways. One is through its stem cell bank, which charges families for collection, processing, and long-term storage services. The other is through its drug development work, where it advances cell therapy candidates such as ProTrans and may earn value through research partnerships, licensing, or future commercialization if its therapies reach the market.
What makes NextCell different is that it sits in two parts of the stem cell value chain at once: it handles storage today while also trying to turn stem cells into medicines for tomorrow. That gives the company a mix of service revenue and higher-risk biotech development, and its customers range from private families using the bank to hospitals, researchers, and future patients who could benefit from its cell therapies.
